Grifols S.A. (NASDAQ:GRFS) shares traded 6.09% higher at $8.53 on Wall Street last session.
In accordance with the data, 5 analysts cover Grifols S.A. (NASDAQ:GRFS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.23 and a low of $9.15, we find $9.69. Given the previous closing price of $8.04, this indicates a potential upside of 20.52 percent. GRFS stock price is now 14.49% away from the 50-day moving average and -9.86% away from the 200-day moving average. The market capitalization of the company currently stands at $7.31B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 3 analysts and a buy by 2. Brokers who have rated the stock have averaged $9.69 as their price target over the next twelve months.
, while ‘Barclays’ rates the stock as ‘Underweight’.
There have been several recent changes in the stakes of large investors in GRFS stock. A new stake in Grifols S.A. shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $6,420,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $4,376,000 in shares of GRFS during the first quarter. In the first quarter, OLD MISSION CAPITAL, LLC acquired a new stake in Grifols S.A. valued at approximately $1,708,000. AQUATIC CAPITAL MANAGEMENT LLC acquired a new stake in GRFS for approximately $662,000. KOSS-OLINGER CONSULTING, LLC purchased a new stake in GRFS valued at around $377,000 in the second quarter. In total, there are 181 active investors with 42.60% ownership of the company’s stock.
Grifols S.A. (NASDAQ: GRFS) opened at $8.06 on Thursday. During the past 12 months, Grifols S.A. has had a low of $5.71 and a high of $13.34. As of last week, the company has a debt-to-equity ratio of 1.56, a current ratio of 2.70, and a quick ratio of 0.90. The fifty day moving average price for GRFS is $7.45 and a two-hundred day moving average price translates $9.46 for the stock.
The latest earnings results from Grifols S.A. (NASDAQ: GRFS) was released for Jun, 2022.
Moreover, the firm recently paid out its quarterly dividend on 06/14/2021. Investors who held shares on 06/04/2021 were paid a $0.456586 dividend. On an annualized basis, this represents a $0.66 dividend and a 7.71% percent yield. There was an ex-dividend date of 06/03/2021 for this dividend.
Grifols S.A.(GRFS) Company Profile
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
